GSK has quit that one
but, of course, the adjuvant had nothing to with it. it was the big pharma's fault
or was it? after all, so many posters here insist that agen's adjuvant MUST be good or else these very smart big pharmas would not be selecting it -- but those same pharmas are so stupid that they waste tons of money and years of time on drugs that don't work?
maybe the problem is that the big pharmas drugs are being paired with an adjuvant that has yet to enhance anything successfully in a trial
according to greatdayisback2013, stocks can run up in advance of the meeting. this is what great day posted,
"Each June, the American Society of Clinical Oncology (ASCO) hosts its annual meeting - an event that's attended by 30,000 people and the scene of 4,000 presentations.
And each May, just ahead of this crucial gathering, a select group of oncology stocks takes investors on a pretty wild ride - almost like clockwork.
That's the "ASCO Effect."
The catalyst for this big run-up - in which some stocks double, triple or quadruple in price (or more) - is well-known. A few weeks ahead of the meeting, ASCO posts drug-research abstracts of some of the presenting companies on its Website; investors look at the clinical-trial results contained in the abstracts, and key on the most-promising players - igniting share rallies so torrid that they're remembered for years."
this could turn out to be a short-lived, low selling drug
there will be too many serious cautions for doctors to feel comfortable prescribing
those voting nay will be the ones that do not want people getting lung cancer
insulin does not belong on lung tissues
however, ultimate approval is likely for subgroups for which the lung cancer may be the lesser of two evils, but that will be a much, much reduced market for MNKD and will require ongoing studies
such a fantasy world you live in
have you noticed the market cap lately
think maybe the chance of any of your assumptions coming to fruition are slim
so much glee and gloating and pounding of chests and boasting this morning
and now turned to raw, foaming at the mouth, anger
tsk, tsk, tsk...
if you had done some research you would have realized this was a major issue
it seems this board has quite a coterie of pompom pumpers so frenetically circle jerking that they have become immune to both facts and logic
bottom line has always been that lungs are not a place to be spraying a growth hormone
wow, but the posts be a flying -- and much spittle, too
looks like a lot of money about to be lost
well, just goes to show that even rank gamblers could benefit by at least a bit of research...
inconvenient truth but no way around that fact
don't know why folks say there is nothing the same with pfizer's drug just because the inhaler was so much different
the bottom line is that they are both delivering insulin to the lungs and, as far as the lungs are concerned, the two are identical and THAT is the problem -- lungs are NOT a place to be spraying a growth hormone
and now you're hoping it gets back to 3.40
also noticed GALE is down 70% since your buy in January
best stick to nose picking, 'cause you aren't much good at trend picking
that was the annual report in February
they will be back on schedule for the quarterly report
and they will absolutely be reporting a loss -- guaranteed
btw, with respect to samsa's post up above about FDA wanting 'tamper' proof -- i think that just indicates how out of touch and misinformed the pompom pumpers on this board are. the FDA wants companies to show abuse resistance not tamper proof, and ipci's own statements admit that rexista is only moderately resistant. that simply is not going to cut it, and that is why they have no partner for it
if it makes bad lungs worse, then it will make good lungs bad
not to mention that the dosage is too dependent on how the inhaler is being used
well, sidney, the actual date is by far the least consequential element of that post
supposedly you agree with the rest
but we are curious, given that you seem to know next Friday is incorrect -- when will ipci report?
i mean, really, do you have any facts in your possession, or do you just come to this board to lob fish from the back benches?
junny, do you not read carefully, or do you just willfully misinterpret what ever you can out of bias? here is what was stated in the press release last August...
"The extra arm of the trial is for patients who may have unusually aggressive cancer, such that they already have progression (tumor recurrence) by the end of 6 weeks of post-surgery radiation treatments as part of standard of care, when eligibility for the DCVax trial is determined."
the third arm is for patients who already had surgery and are already experiencing recurrence. read, read, and reread until you understand that, and THEN understand that because of the recurrence they were NOT eligible for this trial as it has been set up and which can be set up anyway that Northwest and the relevant agency decides
as for your endless repetitious objection to not including these unusually aggressive cases -- which the L vaccine is not even purported to address (though it might prove helpful) -- how about Northwest just seek out some patients deemed likely to die this afternoon, so you could claim with great certainty that, in fact, the L vaccine cannot bring the dead back to life. is that what you're looking for, would that make you happy?
pfizer learned this years ago and pulled their drug
" If Focalin generates just 2.5M Focalin alone will make this worth current market cap."
if you believe that $2.5 million in sales justifies a $100 million market cap then you deserve to lose money here
you make no attempt to dispute any of the facts greg has presented but simply chose to put faith in fantasy and fiction
good luck with that
hmm-mm, five thumbs up in 14 minutes
you certainly love yourself a lot, and you must have fast fingers to be able to change ID's so quickly
but, are you ever going to admit being wrong when you bought, and told everyone to follow your infallible lead, GALE in the 7.40's back in January? i mean you're down 70 percent and, no apology?